EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study

Chungsoo Kim iD, Seonji Kim iD, Dong Yun Lee iD, Eugene Han iD, Yong-Ho Lee iD, Seng Chan You iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70985 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Chungsoo Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Mental Disorders, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health & Welfare, Republic of Korea, Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We evaluated the risk of mental health disorders among glucagon‐like peptide‐1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. Materials and Methods We conducted a nationwide, active‐comparator new‐user cohort study using the Korean claims database from 2012 to 2022. Patients aged ≥ 18 years who initiated GLP1RAs, SGLT2 inhibitors, or DPP4 inhibitors for type 2 diabetes were included. We compared the hazard ratios (HRs) and 95% confidence intervals (CIs) for depression, anxiety, sleep disorders, and suicide using the Cox proportional hazards models after propensity score matching.

Results

The 18 825 GLP1RA users were matched with 623 750 SGLT2 inhibitor users, and 5762 GLP1RA users with 874 902 inhibitor users. Compared with DPP4 inhibitors, GLP1RAs were not associated with increased risks of depression (HR 1.00 [95% CI, 0.83–1.20]), anxiety (0.92 [0.77–1.08]), or sleep disorder (1.14 [0.97–1.33]). In contrast, compared with SGLT2 inhibitors, GLP1RA use was associated with higher risks of depression (1.20 [1.09–1.31]) and anxiety (1.09 [1.00–1.19]). Suicidality events were rare and not observed among GLP1RA users.

Conclusions

Initiation of GLP1RAs was not associated with increased risk of mental health disorders compared with DPP4 inhibitors. Differences in the risk of depression and anxiety were observed compared with SGLT2 inhibitors. These findings suggest that psychiatric safety signals may vary by active comparator and provide real‐world evidence on the psychiatric safety of GLP‐1–based therapies. Further studies incorporating detailed clinical data and high‐risk subgroups are needed to clarify underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsMental DisordersHypoglycemic AgentsHumansMaleFemaleMiddle AgedCohort StudiesDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsAdultAgedRepublic of KoreaDepression

Stichwörter der Autor:innen

DPP4 inhibitorGLP‐1 receptor agonistSGLT2 inhibitoranxiety disorderdepressiontype 2 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.
  • Center for Outcomes Research and Evaluations, Yale New Haven Hospital, New Haven, Connecticut, USA.
  • Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Yonsei Institute for Digital Health, Yonsei University, Seoul, Republic of Korea.
  • Bongdam Forest Mental Health Clinic, Hwaseong, Republic of Korea.
  • Department of Internal Medicine, Keimyung University, School of Medicine, Daegu, Republic of Korea.

ORCID-Profile: Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yong-Ho Lee, Seng Chan You

Förderung

  • Ministry of Health & Welfare, Republic of Korea
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Kim, C., Kim, S., Lee, D. Y., Han, E., Lee, Y. H., & You, S. C. (2026). Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70985

Vancouver

Kim C, Kim S, Lee DY, Han E, Lee YH, You SC. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70985

BibTeX
@article{Kim2026,
  author = {Kim, Chungsoo and Kim, Seonji and Lee, Dong Yun and Han, Eugene and Lee, Yong-Ho and You, Seng Chan},
  title = {Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70985}
}
Kostenlos starten →